Akeso, Inc. ( (HK:9926) ) has issued an announcement.
Akeso, Inc. announced that its PD-1/VEGF bispecific antibody, ivonescimab, combined with chemotherapy, has achieved positive results in a Phase III clinical trial for advanced squamous non-small cell lung cancer (sq-NSCLC). The trial, known as HARMONi-6, demonstrated statistically significant and clinically meaningful progression-free survival benefits compared to tislelizumab plus chemotherapy, with a favorable safety profile. These results position ivonescimab as a promising new treatment option for sq-NSCLC, potentially improving upon current standards of care and enhancing the clinical benefits of immunotherapy.
More about Akeso, Inc.
Akeso, Inc. is a biopharmaceutical company that focuses on the development of innovative antibody drugs. The company is involved in creating treatments for various cancers, including lung cancer, biliary tract cancer, and more, with a strong emphasis on immunotherapy and bi-specific antibodies.
YTD Price Performance: 36.66%
Average Trading Volume: 12,523,384
Technical Sentiment Signal: Sell
Current Market Cap: HK$74.45B
Learn more about 9926 stock on TipRanks’ Stock Analysis page.